The AHA submitted comments June 26 to the House Ways and Means Subcommittee on Health for a hearing about improving value-based care. The AHA shared principles Congress should consider when designing alternative payment models to make participation more attractive for potential participants. Those principles include providing an adequate on-ramp and glidepath to transition to risk; including adequate risk adjustment; allowing voluntary participation and flexible design; balancing risk versus reward; and establishing guardrails to ensure participants don't compete against themselves when they achieve optimal cost savings and outcomes, among others. 

Additionally, the AHA was critical of the Centers for Medicare & Medicaid Services' newly proposed Transforming Episode Accountability Model — a mandatory bundled payment model — and suggested CMS make participation voluntary along with a host of other changes. The AHA also questioned design elements of CMS’ proposed Increasing Organ Transplant Access model, a mandatory payment model for kidney transplants. 

Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The AHA commented June 1 on the Centers for Medicare & Medicaid Services’ skilled nursing facility prospective payment system proposed rule for fiscal year…
Headline
The AHA submitted comments to the Centers for Medicare & Medicaid Services June 1 on the inpatient psychiatric facility prospective payment system proposed…
Headline
The AHA June 1 urged the Centers for Medicare & Medicaid Services to revisit its market basket forecast and work with Congress to reduce the productivity…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…